Tirzepatide is the first FDA-approved dual agonist, activating both the GIP and GLP-1 receptors in a single once-weekly injection. Sold as Mounjaro for type 2 diabetes and Zepbound for obesity, it produces larger blood-sugar and weight reductions than any single GLP-1 medicine tested against it in head-to-head trials.
What exactly is tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide engineered from the human GIP (glucose-dependent insulinotropic polypeptide) sequence and modified so it also switches on the GLP-1 receptor. A fatty-acid side chain lets it bind to albumin in the bloodstream, stretching its half-life to roughly five days, so a single shot covers a full week, according to its StatPearls drug monograph. It is delivered as a subcutaneous injection into the abdomen, thigh, or upper arm.
Unlike older incretin medicines that hit only one receptor, tirzepatide is often called a "twincretin." That dual mechanism is why it sits in its own category rather than alongside the pure GLP-1 receptor agonist drug class.
How does tirzepatide work as a dual agonist?
Both GIP and GLP-1 are incretin hormones your gut releases after a meal to help manage the incoming glucose. Tirzepatide imitates both at the same time, producing four overlapping effects:
- It triggers glucose-dependent insulin release, so insulin rises mainly when blood sugar is elevated, which limits the risk of lows.
- It suppresses glucagon, the hormone that signals the liver to release stored sugar.
- It slows gastric emptying, blunting post-meal glucose spikes and prolonging the feeling of fullness.
- It acts on appetite centers in the brain, reducing hunger and overall food intake.
What does adding the GIP receptor change?
Pure GLP-1 drugs already deliver strong appetite suppression. Layering GIP agonism on top appears to improve insulin sensitivity and how the body stores and burns fat, and it may soften the nausea ceiling that limits how high GLP-1-only drugs can be pushed. The FDA prescribing information describes tirzepatide plainly as a "dual GIP and GLP-1 receptor agonist," and that combined signaling is widely credited for its edge on weight loss.
What are tirzepatide's brand names: Mounjaro vs Zepbound?
Tirzepatide is sold under two brand names made by Eli Lilly. The molecule inside is identical, but the approved use, marketing, and packaging differ. Mounjaro and Zepbound contain the same tirzepatide at the same strengths.
| Brand | Approved use | First approved | Maker |
|---|---|---|---|
| Mounjaro | Type 2 diabetes (glycemic control) | May 2022 | Eli Lilly |
| Zepbound | Chronic weight management; obstructive sleep apnea | November 2023 | Eli Lilly |
What is tirzepatide approved to treat?
- Mounjaro was approved by the FDA in May 2022 as an adjunct to diet and exercise to improve blood sugar in adults with type 2 diabetes.
- Zepbound followed in November 2023 for chronic weight management in adults with obesity, or overweight plus a weight-related condition. In December 2024 it also became the first drug approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
Both are once-weekly injections used alongside lifestyle changes, not as standalone fixes.
How is tirzepatide dosed?
Every patient starts low and steps up slowly so the gut can adjust. The 2.5 mg starting dose is a tolerance-building dose, not a treatment dose. Doses climb by 2.5 mg no sooner than every four weeks, up to a 15 mg ceiling.
| Phase | Dose | Duration |
|---|---|---|
| Starting (tolerance) | 2.5 mg/week | 4 weeks |
| First treatment step | 5 mg/week | 4+ weeks |
| Optional increases | 7.5, 10, 12.5 mg/week | 4+ weeks each |
| Maximum | 15 mg/week | maintenance |
If you tolerate a dose poorly, clinicians often hold or step back rather than push ahead. See the full tirzepatide titration schedule and dose questions for the week-by-week plan.
How effective is tirzepatide?
The pivotal evidence comes from the SURMOUNT (obesity) and SURPASS (diabetes) trial programs.
In SURMOUNT-1, published in the New England Journal of Medicine in 2022, 2,539 adults with obesity or overweight without diabetes took tirzepatide for 72 weeks. Mean weight loss reached about 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, with efficacy-estimand reductions up to 22.5% versus roughly 3% on placebo.
In SURPASS-2, a 40-week head-to-head trial also in the New England Journal of Medicine (2021), all three tirzepatide doses lowered A1C and body weight more than 1 mg semaglutide in people with type 2 diabetes, making it the first incretin to beat semaglutide directly. For a deeper comparison, see tirzepatide vs semaglutide for weight loss.
| Trial | Population | Key result |
|---|---|---|
| SURMOUNT-1 | Obesity, no diabetes | Up to ~22.5% body-weight loss at 72 weeks |
| SURPASS-2 | Type 2 diabetes | Superior A1C and weight loss vs semaglutide 1 mg |
Real-world tirzepatide weight-loss results and timelines tend to track these trial figures when the dose is maintained.
How does tirzepatide differ from single GLP-1 drugs?
The practical difference is the second receptor. Drugs like semaglutide and liraglutide engage only the GLP-1 receptor, while tirzepatide engages both GLP-1 and GIP. In glucose and weight outcomes, that dual action has translated into larger average reductions in the trials that pitted them against each other.
A few features set tirzepatide apart in everyday use:
- One molecule, two indications. The same drug is marketed for diabetes and for obesity under separate names, which can affect insurance coverage and how it is prescribed.
- Slow, fixed titration. The four-week steps exist to limit nausea; rushing them tends to backfire.
- Higher weight-loss ceiling. In head-to-head and cross-trial comparisons, peak weight loss has run several percentage points above semaglutide.
That said, more potency can mean more gastrointestinal effects for some people, and the right medication still depends on individual goals, tolerance, cost, and access rather than potency alone.
What side effects should you expect?
The most common reactions are gastrointestinal: nausea, diarrhea, vomiting, constipation, and reduced appetite, usually worst during dose increases and easing over time. Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent data and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Less common but serious risks include pancreatitis, gallbladder problems, and hypoglycemia when combined with insulin or a sulfonylurea. See the full breakdown of tirzepatide side effects and how to manage them.
Frequently Asked Questions
Is tirzepatide a GLP-1 drug?
Partly. It activates the GLP-1 receptor, but it also activates the GIP receptor, which pure GLP-1 drugs do not. That second target is why it is classified as a dual agonist rather than a standard GLP-1 receptor agonist.
Is tirzepatide stronger than Ozempic?
In SURPASS-2, tirzepatide lowered A1C and body weight more than semaglutide (the drug in Ozempic and Wegovy). Individual results vary, and the best choice depends on your health profile, tolerance, and access.
Does weight come back after stopping tirzepatide?
Trial extensions show most people regain a meaningful share of lost weight after stopping, because the drug's appetite and glucose effects fade once it clears. It is generally treated as a long-term therapy.
Is tirzepatide the same as Ozempic?
No. Ozempic is semaglutide, a single GLP-1 receptor agonist. Tirzepatide is a separate molecule that targets both GIP and GLP-1 receptors.
This article is for general education only and is not medical advice; talk with a licensed clinician before starting or changing any medication.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
- FDA. MOUNJARO (tirzepatide) injection prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
- Farzam K, Patel P. Tirzepatide. StatPearls, NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK585056/
